HC Wainwright Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX)
HC Wainwright began coverage on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a report issued on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $41.00 target price on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Wall Street Zen raised Cidara Therapeutics […]
HC Wainwright began coverage on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a report issued on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $41.00 target price on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Wall Street Zen raised Cidara Therapeutics […]
